Press release
Uveal Melanoma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, and others
Uveal Melanoma Pipeline
In the Uveal Melanoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Uveal Melanoma NDA approvals (if any), and product development activities comprising the technology, Intraocular(Uveal) melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Uveal Melanoma pipeline treatment landscape of the report, click here @ Uveal Melanoma Pipeline- https://www.delveinsight.com/report-store/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Uveal Melanoma Pipeline Report
• DelveInsight's Uveal Melanoma Pipeline analysis depicts a robust space with 25+ active players working to develop 30+ pipeline treatment therapies.
• The leading Uveal Melanoma Companies working in the market include Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, and others.
• Promising Uveal Melanoma Pipeline Therapies in the various stages of development include AEB071, FHD286, Dacarbazine, Ipilimumab, Pembrolizumab, DYP688, IMCgp100, SD-101, BVD-523, Marqibo® (vincristine sulfate liposomes injection), ICON-1, and others.
• On March 2023, Foghom Therapeutics Inc announced a study of phase 1 clinical trials for FHD-286. This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).
• On March 2023, Immunocore Ltd announced a study of phase 2 clinical trials for Dacarbazine. To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
• On March 2023, Novartis Pharmaceuticals announced a study of phase 1 & 2 for DYP688. This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.
Uveal Melanoma Overview
Uveal melanoma is the most common primary intraocular malignancy in adults. Intraocular is a disease in which malignant cells form in the tissues of the eye. Signs of intraocular melanoma include blurred vision or a dark spot on the iris. While development of uveal melanoma is largely considered to be a sporadic event, certain risk factors including light iris color, light skin color, ability to tan and others predispose individuals to Uveal melanoma.
To explore more information on the latest breakthroughs in the Uveal Melanoma Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Uveal Melanoma Emerging Drugs Profile
• BVD-523: BioMed Valley Discoveries, Inc
• AU-011: Aura Biosciences, Inc
• PAC-1: Vanquish Oncology
Uveal Melanoma Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Intraocular (Uveal) melanoma. The Uveal Melanoma companies which have their Intraocular (Uveal) melanoma drug candidates in the most advanced stage, i.e. phase II include BioMed Valley Discoveries, Inc.
Request a sample and discover the recent advances in Uveal Melanoma Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Uveal Melanoma Drugs and Companies
• AEB071: Novartis Pharmaceuticals
• FHD-286: Foghorn Therapeutics Inc
• Dacarbazine: Immunocore Ltd
• DYP688: Novartis Pharmaceuticals
• IMCgp100: Immunocore Ltd
Uveal Melanoma Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Uveal Melanoma Therapeutics Market include-
Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, and others.
Dive deep into rich insights for drugs for Uveal Melanoma Pipeline, click here for Uveal Melanoma Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Uveal Melanoma Pipeline Report
• Coverage- Global
• Companies- Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, and others.
• Pipeline Therapies- AEB071, FHD286, Dacarbazine, Ipilimumab, Pembrolizumab, DYP688, IMCgp100, SD-101, BVD-523, Marqibo® (vincristine sulfate liposomes injection), ICON-1, and others.
• Uveal Melanoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Uveal Melanoma Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Intraocular (Uveal) melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Intraocular (Uveal) melanoma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Intraocular (Uveal) melanoma Collaboration Deals
9. Late Stage Products (Preregistration)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BVD-523: BioMed Valley Discoveries Inc
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Intraocular (Uveal) melanoma Key Companies
23. Intraocular (Uveal) melanoma Key Products
24. Intraocular (Uveal) melanoma- Unmet Needs
25. Intraocular (Uveal) melanoma- Market Drivers and Barriers
26. Intraocular (Uveal) melanoma- Future Perspectives and Conclusion
27. Intraocular (Uveal) melanoma Analyst Views
28. Intraocular (Uveal) melanoma Key Companies
29. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveal Melanoma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, and others here
News-ID: 3140445 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for Uveal
Uveal Neoplasms Market Detailed Industry Report Analysis 2025-2034
Introduction
Uveal neoplasms, also referred to as uveal melanomas and related tumors, are rare malignancies that arise from the uveal tract of the eye, which includes the iris, ciliary body, and choroid. Among these, uveal melanoma is the most common primary intraocular malignancy in adults. Despite its rarity, it carries high morbidity and mortality risks, especially when it metastasizes to the liver.
Traditional management strategies - including surgery, radiotherapy, and enucleation -…
Metastatic Uveal Melanoma Therapeutics Market: An In-Depth Analysis
The Metastatic Uveal Melanoma Therapeutics market was valued at USD 1.23 billion in 2023 and is projected to reach approximately USD 3.00 billion by 2033, growing at an estimated CAGR of around 8.9% from 2024 to 2033.
Metastatic Uveal Melanoma Therapeutics Market Overview
The Metastatic Uveal Melanoma Therapeutics market is evolving rapidly with the emergence of novel targeted and immunotherapeutic treatments addressing this rare and aggressive cancer. Increasing research into tumor-specific pathways…
Global Uveal Melanoma Treatment Market Will Generate Record Revenue by 2028
This Uveal Melanoma Treatment market report is the product of thorough market study and comments on important factors that influence financial decision. Here, helpful insights on customer demands are provided in order to launch the best product or service on the market. COVID-19's detrimental effects on the world economy system are also captured in this way. As a result of the pandemic, some businesses experienced considerable financial losses. Several businesses…
Uveal Melanoma Therapeutics- Clinical Trials & Results | HARMONIC PHARMA, Immuno …
Uveal melanoma is the most common primary malignant tumour of intraocular malignancy, arises from melanocytes in the iris, and ciliary body.
Download the sample report @ https://www.pharmaproff.com/request-sample/1121
The most common symptoms of uveal carcinoma include blurred vision, photopsia, visual field loss, visible tumour, pain, and metamorphopsia. The management of uveal melanoma can be divided into globe-preserving therapy or enucleation. Globe-preserving therapies can broadly classified into radiation, surgical, and laser therapy.
Get…
Uveal Melanoma Global Market Research Report 2025
Uveal Melanoma Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/uveal-melanoma-market/80986
The report firstly introduced the Uveal Melanoma basics: definitions, classifications, applications and…
Uveal Melanoma Market By Analysis of Major Industry Segments 2024
Global Uveal Melanom Market: Overview
Uvea is present posterior to sclera and the cornea and has three parts namely, iris, ciliary body and choroid. Uveal melanoma is referred as the cancer of the parts of eye including the iris choroid and ciliray body. It is the condition in which the tumors arise from the melanocytes residing within the uva responsible for the color of the eye. Though is a rare…
